RE-BVS – Piemonte Repository

Sfoglia per AUTORE
BUTI S
Collezione ASL Torino 4

Items : 6

First-line avelumab for patients with PD-L1-positive metastatic or locally advanced urothelial cancer who are unfit for cisplatin. in Annals of oncology : official journal of the European Society for Medical Oncology / Ann Oncol. 2022 Nov;33(11):1179-1185. doi: 10.1016/j.annonc.2022.07.011. Epub 2022 Aug 2.

2022
ASL Torino 4
AOU San Luigi di Orbassano

Rizzo M; Spina F; Milesi L; De Vivo R; Masini C; Merler S; Ermacora P; Verri E; Galli L; Carella C; Santini D; Buti S; Caserta C; Buttigliero C; Battelli N; Ciccarese C; Brunelli M; Iacovelli R; Sperduti I; Fornarini G; Tortora G;

Nivolumab in Combination with Stereotactic Body Radiotherapy in Pretreated Patients with Metastatic Renal Cell Carcinoma. Results of the Phase II NIVES Study. in European urology / Eur Urol. 2022 Mar;81(3):274-282. doi: 10.1016/j.eururo.2021.09.016. Epub 2021 Oct 1.

2022
ASL Torino 4
AOU San Luigi di Orbassano

Fantinel E; Timon G; Ciammella P; Buttigliero C; Baier S; Morelli F; Nole F; Caffo O; Procopio G; Lohr F; Bruni A; Vitale MG; Mucciarini C; Mazzarotto R; Zampiva I; Buti S; Salaroli F; Bellia RS; De Giorgi U; Iotti C; Masini C; Carlinfante G; Berselli A; Pinto C;

High familial burden of cancer correlates with improved outcome from immunotherapy in patients with NSCLC independent of somatic DNA damage response gene status. in Journal of hematology & oncology / J Hematol Oncol. 2022 Jan 21;15(1):9. doi: 10.1186/s13045-022-01226-2.

2022
ASL Torino 4
AO Ordine Mauriziano
AOU San Luigi di Orbassano
AOU Novara

Pinato DJ; Russo A; Russano M; Porzio G; Tiseo M; Ficorella C; Addeo A; Banna GL; Friedlaender A; Metro G; Spinelli GP; Passiglia F; Migliorino MR; Ricciardi S; Pecci F; Zoratto F; De Tursi M; Di Marino P; Mansueto G; Tuzi A; Gori S; Della Gravara L; Rastelli F; Chiari R; Macerelli M; Marchetti P; Gelibter A; Antonuzzo L; Berardi R; et alii...

Cabozantinib beyond progression improves survival in advanced renal cell carcinoma patients: the CABEYOND study (Meet-URO 21). in Expert review of anticancer therapy / Expert Rev Anticancer Ther. 2022 Jan;22(1):115-121. doi: 10.1080/14737140.2022.2002688. Epub 2021 No

2022
ASL Torino 4
AO Ordine Mauriziano
AOU San Luigi di Orbassano

Pignata S; De Braud FG; Verzoni E; Procopio G; Ottini A; Guadalupi V; Claps M; Sepe P; Buttigliero C; Stellato M; Roviello G; Di Lorenzo G; Mucciarini C; Messina C; Santini D; Casadei C; Sorarù M; Buti S; De Giorgi U; Bimbatti D; Di Maio M; Zattarin E; Mennitto A;

First line avelumab in PD-L1+ve metastatic or locally advanced urothelial cancer (aUC) patients unfit for cisplatin (cis): The ARIES trial in Journal of Clinical Oncology

2022
ASL Torino 4

Sperduti I; Fornarini G; Masini C; Aprile G; Milesi L; Spina F; Rizzo M; Verri E; Ermacora P; Milella M; Buti S; Santini D; Naglieri E; Galli L; Battelli N; Buttigliero C; Caserta C; Ciccarese C; Brunelli M; Iacovelli R;

INfluenza Vaccine Indication During therapy with Immune checkpoint inhibitors: a multicenter prospective observational study (INVIDIa-2). in Journal for immunotherapy of cancer / J Immunother Cancer. 2021 May;9(5):e002619. doi: 10.1136/jitc-2021-002619.

2021
AO Ordine Mauriziano
ASL Torino 4
AOU Alessandria

Buti S; Filetti M; Migliorino MR; Russo A; Negrini G; Pinto C; Di Costanzo F; Tognetto M; Tiseo M; Leonardi F; Guadalupi V; Zucali PA; Sorarù M; Laera L; Camerini A; Cinieri S; Baldessari C; Zustovich F; Mencoboni M; Accettura C; Fratino L; Guaitoli G; Rizzo M; Verderame F; Montesarchio V; Casadei C; Ficorella C; Grossi F; Rossi E; et alii...